Clinical Trials Logo

Clinical Trial Summary

Intermittent episodes of hypoxemia and/or bradycardia, also defined as cardio-respiratory events (CRE) are very frequent in preterm infants and may result in transient hypoxia and hypoperfusion of target organs, with possible clinical implications. The hemodynamic instability that characterizes the first 72 hours of life, also called as transitional period, place preterm infants at high risk of complications and may contribute to enhance fluctuations in end-organ perfusion and oxygenation induced by CRE. In this study we aimed to explore cardiovascular and cerebrovascular changes determined by different CRE types in preterm infants during the transitional period.


Clinical Trial Description

Intermittent episodes of hypoxemia and/or bradycardia, also defined as cardio-respiratory events (CRE) are very frequent in preterm infants and may result in transient hypoxia and hypoperfusion of target organs, with possible clinical implications. The hemodynamic instability that characterizes the first 72 hours of life, also called as transitional period, place preterm infants at high risk of complications and may contribute to enhance fluctuations in end-organ perfusion and oxygenation induced by CRE. Moreover, during this period, several clinical variables (e.g., antenatal steroid administration, gestational age [GA], patent ductus arteriosus [PDA], respiratory support etc.) may contribute to modulate the hemodynamic fluctuations in response to CRE.

Hence, this study aims:

- to explore changes in the main cardiovascular and cerebrovascular parameters elicited by different CRE types

- to evaluate whether different antenatal, perinatal and postnatal factors may influence the observed cardiovascular and cerebrovascular responses to CRE.

Infants born at S. Orsola-Malpighi Hospital are consecutively enrolled in this observational, prospective study if fulfilling the following eligibility criteria: gestational age (GA) <32 weeks' gestation, birth weight <1500 g, 0-12 hours of life, written informed consent obtained from the parents/legal guardians of each infant.

As routinely performed in infants with the eligible characteristics, the enrolled infants undergo a simultaneous, continuous and non-invasive monitoring of

- peripheral oxygen saturation (SpO2) and heart rate (HR) using a pulse oximeter

- cerebral tissue oxygenation index (cTOI) and cerebral total hemoglobin index (cTHI), which represents a proxy of cerebral blood flow, using near infrared spectroscopy. Cerebral fraction of oxygen extraction (cFTOE) is also calculated as follows: (SpO2-cTOI)/SpO2.

- cardiovascular parameters (cardiac output [CO], stroke volume [SV], cardiac contractility index [ICON], systemic vascular resistance [SVR]) using electrical cardiometry.

In the enrolled infants, each monitoring device is connected via a RS232 cable to a laptop running ICM+® (https://icmplus.neurosurg.cam.ac.uk/, Cambridge Enterprise, UK), a software tool that allows a real-time synchronized multi-parametric data collection, which recorded the above mentioned parameters continuously, from the time of enrollment up to 72 hours of life.

Cardiorespiratory event types are classified on the basis of SpO2 and HR values as follows:

- isolated desaturation (ID): SpO2 <85% and classified into mild (SpO2 80-84%), moderate (SpO2 70-79%) and severe (SpO2 <70%).

- isolated bradycardia (IB): any HR drop <100 bpm or >30% from baseline values, calculated daily over the first 72 hours of life

- desaturation and bradycardia occurring within a 60-sec time window: combined events (DB).

The following antenatal and neonatal data are tracked down on a specific case report form: GA, antenatal steroids (complete course vs. incomplete course or not given) evidence of reversed end-diastolic flow at antenatal umbilical Doppler (uREDF) (present vs. absent); ventilatory status over the first 72 hours of life (continuous positive airway pressure [CPAP] vs. nasal cannulas or self-ventilating in air [SVIA]); surfactant administration; development of IVH over the first 72 hours of life.

A screening echocardiogram is routinely performed at the time of enrollment and repeated 6-12 hourly in the presence of a patent ductus arteriosus (PDA) or 12-24 hourly if there is no evidence of PDA. Based on echocardiographic features, the ductal status is classified as follows: no evidence of PDA (noPDA), restrictive PDA (rPDA; restrictive shunt pattern and left atrium to aortic root ratio [LA:Ao] ratio <1.5), hemodynamically significant PDA (hsPDA; pulsatile shunt pattern, LA:Ao ratio ≥1.5 or presence of reversed end-diastolic flow either in the descending aorta or in the anterior cerebral artery).

For statistical analysis, percentage changes of cardiovascular (CO, ICON, SVR) and cerebrovascular (cTOI, cTHI, cFTOE) parameters will be compared between different CRE types (ID, DB and IB) using Kruskal-Wallis test. Generalized estimating equation (GEE) models will be used to analyze the concomitant effect of clinical variables (e.g., GA, uREDF, antenatal steroids, ductal and ventilatory status etc.) on the percentage changes of the study parameters. IBM SPSS, version 25.0, will be used for statistical analysis. The significance level is set at p<0.05. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04184245
Study type Observational
Source Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi
Contact
Status Completed
Phase
Start date February 22, 2018
Completion date January 3, 2020

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Completed NCT05502510 - Assessing the Effectiveness and Efficacy of the MyHealthyPregnancy Application
Not yet recruiting NCT03418012 - Prevention of sPTB With Early Cervical Pessary Treatment in Women at High Risk for PTB N/A
Not yet recruiting NCT03418311 - Cervical Pessary Treatment for Prevention of s PTB in Twin Pregnancies on Children`s Long-Term Outcome N/A
Completed NCT02993744 - Maternal Inflammatory Parameters Within Routine Treatment With Betamethasone N/A
Active, not recruiting NCT02673216 - Infection and Adverse Pregnancy Outcome
Completed NCT01683565 - Preemie Tots: A Pilot Study to Understand the Effects of Prematurity in Toddlerhood Phase 4
Completed NCT01412931 - Protein and Ultrasound Indicators of Preterm Birth N/A
Completed NCT01460576 - Improving Prematurity-Related Respiratory Outcomes at Vanderbilt N/A
Completed NCT02606058 - The Australian Placental Transfusion Study (APTS): Should Very Pre Term Babies Receive a Placental Blood Transfusion at Birth Via Deferring Cord Clamping Versus Standard Cord Clamping Procedures? N/A
Terminated NCT03715530 - Use of Placental Alpha Microglobulin-1(PAMG-1) to Diagnose Premature Rupture of Membranes in Pregnant Women N/A
Completed NCT00422526 - Progesterone for Prevention of Preterm Birth in Women With Short Cervix: Randomized Controlled Trial Phase 3
Enrolling by invitation NCT04251260 - Effectiveness of Positioning in Preterm Neonates N/A
Completed NCT03668860 - India Dexamethasone and Betamethasone Phase 1
Recruiting NCT03638037 - Correlation Between Maternal Vitamin D Level And Preterm Birth
Completed NCT02225353 - Efficacy Study of a Cervical Pessary Containing Progesterone for the Prevention of Preterm Delivery Phase 2
Recruiting NCT03992534 - The FLIP-1 Study: Vaginal Lactobacillus Supplementation in Women at High Risk of Preterm Birth Phase 1
Completed NCT03144141 - Association Between EHG and Risk of Preterm Delivery in Women Hospitalized for Threatened Premature Delivery N/A
Completed NCT05210985 - Examination of the Relationship Between Home Affordances With Development
Completed NCT04021654 - What is the Future of Vulnerable New-borns